Publications
5 shownInterim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
The safety and immunogenicity profiles of Ad26.COV2.S support further development of this vaccine candidate. (Funded by Johnson & Johnson and the Biomedical Advanced Research an...
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
A single dose of Ad26.COV2.S protected against symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection and was effective against severe-critical disease, including hospitaliz...
DNA vaccine protection against SARS-CoV-2 in rhesus macaques
Prototype DNA vaccines for SARS-CoV-2 The development of a vaccine to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an urgent biomedical need. ...
Frequent Co-Authors
Researcher Info
- h-index
- 5
- Publications
- 5
- Citations
- 7,160
- Institution
- Janssen (Belgium)
External Links
Identifiers
- ORCID
- 0000-0001-5127-4659
Impact Metrics
h-index
5
h-index: Number of publications with at least h citations each.